Cigna Investments’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $603K | Sell |
967
-1
| -0.1% | -$681 | 0.08% | 220 |
|
|
2026
Q1 | $748K | Sell |
968
-14
| -1% | -$10.7K | 0.12% | 161 |
|
|
2025
Q4 | $758K | Sell |
982
-50
| -5% | -$34K | 0.11% | 157 |
|
|
2025
Q3 | $580K | Hold |
1,032
| – | – | 0.08% | 209 |
|
|
2025
Q2 | $542K | Sell |
1,032
-20
| -2% | -$11.2K | 0.09% | 213 |
|
|
2025
Q1 | $667K | Sell |
1,052
-26
| -2% | -$17.9K | 0.12% | 169 |
|
|
2024
Q4 | $768K | Sell |
1,078
-9
| -0.8% | -$7.55K | 0.13% | 151 |
|
|
2024
Q3 | $1.14M | Sell |
1,087
-15
| -1% | -$16.7K | 0.2% | 98 |
|
|
2024
Q2 | $1.16M | Buy |
1,102
+6
| +0.5% | +$5.82K | 0.21% | 93 |
|
|
2024
Q1 | $1.05M | Sell |
1,096
-6
| -0.5% | -$5.71K | 0.2% | 109 |
|
|
2023
Q4 | $967K | Sell |
1,102
-17
| -2% | -$14K | 0.2% | 114 |
|
|
2023
Q3 | $921K | Sell |
1,119
-158
| -12% | -$124K | 0.21% | 103 |
|
|
2023
Q2 | $918K | Buy |
1,277
+5
| +0.4% | +$3.85K | 0.17% | 120 |
|
|
2023
Q1 | $1.05M | Sell |
1,272
-26
| -2% | -$19.6K | 0.21% | 105 |
|
|
2022
Q4 | $937K | Buy |
1,298
+4
| +0.3% | +$2.95K | 0.19% | 115 |
|
|
2022
Q3 | $891K | Sell |
1,294
-55
| -4% | -$34.6K | 0.2% | 107 |
|
|
2022
Q2 | $798K | Sell |
1,349
-489
| -27% | -$318K | 0.16% | 137 |
|
|
2022
Q1 | $1.28M | Sell |
1,838
-533
| -22% | -$337K | 0.16% | 126 |
|
|
2021
Q4 | $1.5M | Sell |
2,371
-862
| -27% | -$530K | 0.12% | 138 |
|
|
2021
Q3 | $1.96M | Sell |
3,233
-111
| -3% | -$68.9K | 0.15% | 128 |
|
|
2021
Q2 | $1.87M | Sell |
3,344
-403
| -11% | -$204K | 0.13% | 137 |
|
|
2021
Q1 | $1.77M | Buy |
3,747
+21
| +0.6% | +$10.2K | 0.12% | 152 |
|
|
2020
Q4 | $1.8M | Buy |
3,726
+382
| +11% | +$206K | 0.14% | 138 |
|
|
2020
Q3 | $1.87M | Sell |
3,344
-30
| -0.9% | -$18.2K | 0.18% | 109 |
|
|
2020
Q2 | $2.1M | Buy |
3,374
+1,032
| +44% | +$586K | 0.2% | 99 |
|
|
2020
Q1 | $1.14M | Buy |
2,342
+150
| +7% | +$61.9K | 0.15% | 155 |
|
|
2019
Q4 | $741K | Sell |
2,192
-222
| -9% | -$74.7K | 0.08% | 292 |
|
|
2019
Q3 | $739K | Buy |
2,414
+100
| +4% | +$29.6K | 0.08% | 301 |
|
|
2019
Q2 | $705K | Sell |
2,314
-70
| -3% | -$23.3K | 0.08% | 298 |
|
|
2019
Q1 | $978K | Buy |
2,384
+19
| +0.8% | +$7.82K | 0.11% | 237 |
|
|
2018
Q4 | $883K | Sell |
2,365
-60
| -2% | -$22K | 0.07% | 194 |
|
|
2018
Q3 | $822K | Sell |
2,425
-123
| -5% | -$46.8K | 0.07% | 229 |
|
|
2018
Q2 | $879K | Sell |
2,548
-392
| -13% | -$123K | 0.06% | 269 |
|
|
2018
Q1 | $1.01M | Sell |
2,940
-61
| -2% | -$21.2K | 0.07% | 253 |
|
|
2017
Q4 | $1.13M | Sell |
3,001
-114
| -4% | -$46.2K | 0.07% | 222 |
|
|
2017
Q3 | $1.39M | Buy |
3,115
+74
| +2% | +$35.2K | 0.09% | 167 |
|
|
2017
Q2 | $1.49M | Sell |
3,041
-156
| -5% | -$68.3K | 0.1% | 154 |
|
|
2017
Q1 | $1.24M | Buy |
3,197
+356
| +13% | +$132K | 0.09% | 218 |
|
|
2016
Q4 | $1.04M | Buy |
+2,841
| New | +$1.08M | 0.11% | 229 |
|
Other funds holding REGN
Cigna Investments's REGN Position: Q2 2026 in Review
Cigna Investments reduced its Regeneron Pharmaceuticals (REGN) stake by 0.1% in Q2 2026, selling an estimated $681 and leaving 967 shares worth $603K. The position accounts for 0.08% of the portfolio, ranked #220.
Cigna Investments first reported a position in REGN in Q4 2016 and has held it in 39 quarters since. The position peaked at $2.1M in Q2 2020. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Cigna Investments held 967 shares of Regeneron Pharmaceuticals worth $603K as of Q2 2026.
- Cigna Investments sold 1 Regeneron Pharmaceuticals share in Q2 2026, an estimated $681.
- Regeneron Pharmaceuticals made up 0.08% of Cigna Investments's portfolio in Q2 2026, its #220 holding.
- Cigna Investments first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 39 quarters since.
- Cigna Investments's Regeneron Pharmaceuticals position peaked at $2.1M in Q2 2020.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Cigna Investments's 13F filing for Q2 2026, filed 21 Jul 2026.